Last checked at 15 May 2013 07:00
For immediate release | 15 May 2013 |
RNS REACH
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Alliance Pharma to present at Proactive Investors Forum
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce that John Dawson, CEO of Alliance Pharma, will be presenting on the Company at an upcoming Proactive Investors Forum on Thursday 16 May 2013 in London.
The event starts at 6.00pm and is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, buy and sell side analysts and journalists.
The event will be held at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, London W1J 5EB in the Charles Suite.
For further information, and to register, please go to:
http://www.proactiveinvestors.co.uk/register/event_details/189
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive | |
Richard Wright, Finance Director | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles www.buchanan.uk.com | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Oliver Cardigan | |
Corporate Broking: David Poutney |
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.